Sinovac Biotech Ltd. is a biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. The company is based in Beijing, China. Sinovac's commercialized vaccines include Healive , Bilive , Anflu , Panflu and PANFLU.1 . Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine.Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines. Wikipedia.
Liu Y.,Sinovac Biotech
Human vaccines & immunotherapeutics
Influenza viruses cause annual winter epidemics globally and influenza vaccination is most effective way to prevent the disease or severe outcomes from the illness, especially in developing countries. However, the majority of the world's total production capacity of influenza vaccine is concentrated in several large multinational manufacturers. A safe and effective preventive vaccine for the developing countries is urgent. Anflu®, a Chinese domestic preservative-free, split-virus trivalent influenza vaccine (TIV), was introduced by Sinovac Biotech Ltd. in 2006. Until now, 20.6 million doses worldwide of Anflu® were sold. Since 2003, 13 company-sponsored clinical studies investigating the immunogenicity and safety of Anflu® have been completed, in which 6642 subjects participated and were vaccinated by Anflu®. Anflu® was generally well tolerated in all age groups, and highly immunogenic in healthy adults and elderly and exceeded the licensure criteria in Europe. This review presents and discusses the experience with Anflu® during the past decade. A new Chinese domestic, preservative-free, unadjuvanted, inactivated split-virus trivalent influenza vaccine (TIV), Anflu®, was introduced into human clinical trials in 2003 and then licensed in China in 2006. The vaccine contains 15 µg/0.5 ml hemagglutinin from each of the 3 influenza virus strains (including an H1N1 influenza A virus subtype, an H3N2 influenza A virus subtype, and an influenza B virus) that are expected to be circulating in the up-coming influenza season. The clinical data pertaining to Anflu® will be reviewed and compared with other TIVs available at present. Source
News Article | June 11, 2015
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vrgbgj/h1n1_vaccines) has announced the addition of the "H1N1 Vaccines - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for H1N1 Vaccines in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 33 companies including many key and niche players such as 3. AN INSIGHT INTO THE GLOBAL VACCINES MARKET
News Article | April 15, 2015
The report “Tetanus - Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Tetanus. Tetanus is a acute infectious disease of humans and other animals, caused by toxins produced by the bacillus Clostridium tetani and characterized by rigidity and spasms of the voluntary muscles. The initial symptoms of tetanus include irritable and sore muscles. Muscles also get stiff and become cramped and body starts to feel tired. Swallowing food also becomes a problem. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/tetanus-pipeline-review-h1-2015-market-report.html . The report also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. Companies discussed in this Tetanus – Pipeline Review, H1 2015 report include Beijing Minhai Biotechnology Co., Ltd, Bharat Biotech International Limited, Biological E. Limited, Daiichi Sankyo Company, Limited, Green Cross Corporation, Indian Immunologicals Limited, LG Life Sciences, Ltd., Novartis AG, Panacea Biotec Limited, Prometheon Pharma, LLC, Sanofi, Sanofi Pasteur SA, Serum Institute of India Limited, Sinovac Biotech Ltd. and Zydus Cadila Healthcare Limited. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Drug Profiles mentioned in this report are (diphtheria + tetanus + pertussis (acelluar) + poliovirus (types 1, 2 ,3)) vaccine, (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis + haemophilus influenza [serogroup B]) vaccine, diphtheria + pertussis + tetanus + hepatitis [serotype B] + haemophilus influenza [serotype B] vaccine, diphtheria + pertussis + tetanus vaccine, diphtheria + pertussis + tetanus vaccine, diphtheria + tetanus + pertussis (acellular) vaccine, diphtheria + tetanus + pertussis (acellular) vaccine, diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [type B] + polio (pentavalent) vaccine, diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [type B] + polio (hexavalent) vaccine, diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine, diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] (pentavalent) vaccine, diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine, diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine, diphtheria + tetanus+ pertussis (whole cell) vaccine, diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine, diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine, diphtheria + tetanus + pertussis (whole-cell) vaccine, diphtheria + tetanus vaccine, DTaP Vaccine, GC-1107, GC-3111A, tetanus + diphtheria + pertussis (acellular) vaccine, tetanus vaccine and VN-0103. Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=356481 . (This is a premium report priced at US$2000 for a single user License.) Featured News & Press Releases cover by this report include: Nov 14, 2014: Biological E To Supply Pentavalent Vaccine For Telangana State Immunization Program 78, Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine 78, Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age 79, Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 79, Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 80, Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 81, Jun 22, 2012: Sanofi Pasteur's Hexaxim Receives Positive Opinion From European Medicines Agency 82, Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis 83, Jun 13, 2005: U.S. FDA Licenses sanofi pasteur's ADACEL Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis 83 and Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine 84. Explore more reports on Pharmaceuticals industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals . About Us: RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
News Article | June 11, 2015
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/p55ckm/tetanus) has announced the addition of the "Tetanus - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
News Article | September 18, 2015
Mumps - Pipeline Review, H2 2015 and Viral Partnering Terms and Agreements are the latest 2015 market research reports addition to the infectious disease therapeutics segment of pharmaceuticals business intelligence collection in RnRMarketResearch.com. Complete report on mumps pipeline review spread across 44 pages, taking about 8 companies, multiple drug profiles and supported with 23 tables and 9 figures is now available at http://www.rnrmarketresearch.com/mumps-pipeline-review-h2-2015-market-report.html . This report provides comprehensive information on the therapeutic development for Mumps, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mumps and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage by studying the mumps pipeline review. It strengthens R&D pipelines of mumps by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. This mumps pipeline review research provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. It helps in identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Develop strategic initiatives by understanding the focus areas of leading companies active in mumps pipeline, identify and understand important and diverse types of therapeutics under development for Mumps as well as plan mergers and acquisitions effectively by identifying key players of the most promising mumps pipeline with the help of this report. The research also helps in planning corrective measures for pipeline projects by understanding Mumps pipeline depth and focus of Indication therapeutics, developing and designing in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope as well as modifying the mumps therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from mumps pipeline. Companies mentioned in this mumps pipeline review report include Beijing Minhai Biotechnology Co., Ltd, Beijing Tiantan Biological Products Co., Ltd., China National Pharmaceutical Group Corporation, GlaxoSmithKline Plc, Organic Vaccines, Prometheon Pharma, LLC, Sinovac Biotech Ltd. and Zydus Cadila Healthcare Limited. Drug profiles covered in this mumps pipeline research are Cell Therapy for Measles, Mumps and Rubella, measles + mumps + rubella + varicella vaccine, measles + mumps + rubella vaccine, measles [strain schwarz] + mumps [strain RIT 4385] + rubella [strain wistar RA 27/3] vaccine and mumps vaccine. Order a copy of Mumps - Pipeline Review, H2 2015 market research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=415878 . The second research titled Viral Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the viral partnering deals and agreements entered into by the world's leading healthcare companies. Delivery of this report will take 1-3 working days after purchase. Topics like trends in viral partnering deals, average deal terms for headline, upfront and royalty by stage of development, viral partnering agreement structure, viral partnering contract documents, top viral deals by value and most active viral dealmakers are covered in this research study. The report provides a detailed understanding and analysis of how and why companies enter viral partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors viral technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report contains over 850 links to online copies of actual viral deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. In addition, a comprehensive appendix is provided with each report of all viral partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in viral partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of viral technologies and products. Comprehensive table of contents and more on this viral partnering terms and agreements report is available at http://www.rnrmarketresearch.com/viral-partnering-terms-and-agreements-market-report.html . Explore more reports on overall therapeutics market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics . About Us: RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets.